BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30406360)

  • 1. The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.
    Løitegård T; Berntzen DT; Thiis-Evensen E
    Ann Nucl Med; 2019 Mar; 33(3):147-152. PubMed ID: 30406360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.
    Kaemmerer D; Twrznik M; Kulkarni HR; Hörsch D; Sehner S; Baum RP; Hommann M;
    Ann Surg; 2021 Jul; 274(1):e45-e53. PubMed ID: 33030849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis.
    Saravana-Bawan B; Bajwa A; Paterson J; McEwan AJB; McMullen TPW
    Clin Nucl Med; 2019 Sep; 44(9):719-727. PubMed ID: 31205149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?
    Sowa-Staszczak A; Chrzan R; Pach D; Stefańska A; Tomaszuk M; Buziak-Bereza M; Kołodziej M; Przybylik-Mazurek E; Hubalewska-Dydejczyk A
    Clin Imaging; 2012; 36(4):360-4. PubMed ID: 22726975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland.
    Pfeifer AK; Gregersen T; Grønbæk H; Hansen CP; Müller-Brand J; Herskind Bruun K; Krogh K; Kjær A; Knigge U
    Neuroendocrinology; 2011; 93(3):189-96. PubMed ID: 21335949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
    Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
    Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
    Kalshetty A; Ramaswamy A; Ostwal V; Basu S
    Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors.
    Yalchin M; Oliveira A; Theocharidou E; Pencharz D; Navalkissoor S; Quigley AM; Walker M; Caplin M; Toumpanakis C
    Clin Nucl Med; 2017 Mar; 42(3):e135-e141. PubMed ID: 27922860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
    Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage peptide receptor radionuclide therapy with [
    van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.
    Thiis-Evensen E; Poole AC; Nguyen HT; Sponheim J
    BMC Cancer; 2020 May; 20(1):466. PubMed ID: 32448245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.
    van Vliet EI; Krenning EP; Teunissen JJ; Bergsma H; Kam BL; Kwekkeboom DJ
    J Nucl Med; 2013 Oct; 54(10):1689-96. PubMed ID: 24084705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic efficacy of 177Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis.
    Wang LF; Lin L; Wang MJ; Li Y
    Medicine (Baltimore); 2020 Mar; 99(10):e19304. PubMed ID: 32150065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.